Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019

Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019

Bibliographic Details
Main Authors:	Marco Rossato, Angelo Di Vincenzo
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2020-07-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2020.20

Similar Items

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
by: Maki Komiyama, et al.
Published: (2020-07-01)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
by: Nitesh Gupta, et al.
Published: (2020-01-01)

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers
by: Neil Poulter, et al.
Published: (2006-06-01)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Myla E. Moretti, et al.
Published: (2012-01-01)

Angiotensin Converting Enzyme Inhibitor/Angiotensin II Receptor Blockers and Pneumonia risk
by: Chia-Lin Liu, et al.
Published: (2010)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Combination of aliskiren with angiotensin-converting enzyme-inhibitor and angiotensin receptor blocker — mechanism of action
by: Luis M Ruilope
Published: (2008-03-01)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
by: Hye-Ran Jun, et al.
Published: (2021-01-01)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
by: Zhang C, et al.
Published: (2021-02-01)

Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria
by: Ha Yeon Kim, et al.
Published: (2014-12-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Safety and efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic allograft injury
by: P R Shah, et al.
Published: (2011-01-01)

Is there any difference between angiotensin converting enzyme inhibitors and angiotensin receptor blockers for heart failure?
by: Carmen Rain, et al.
Published: (2015-07-01)

Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker in preventing stroke among hypertension patients
by: Pi-huei Chao, et al.
Published: (2009)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
by: Amer Harky, et al.
Published: (2021-01-01)

Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
by: Domenic A Sica
Published: (2002-06-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
by: Valentina Carubelli, et al.
Published: (2021-06-01)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
by: John D Bisognano, et al.
Published: (2007-11-01)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
by: Gábor Kriszta, et al.
Published: (2021-03-01)

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19
by: Azadeh Khalili, et al.
Published: (2021-07-01)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality of Coronary Artery Bypass Grafting
by: Ahmad Sharafi, et al.
Published: (2015-10-01)

Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
by: Semaan G. Kosseifi, et al.
Published: (2009-12-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

Comparison of registration parameters of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in different countries
by: A F Garaeva, et al.
Published: (2018-08-01)

Prescription Patterns of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Chronic Kidney Disease
by: Pei-Tzu Wang, et al.
Published: (2008)

The Renoprotective Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Chronic Kidney Disease
by: Wen-Chuan Lin, et al.
Published: (2002)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2016)

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
by: Nicolás Roberto Robles, et al.
Published: (2009-12-01)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
by: Wenjun Wang, et al.
Published: (2021-01-01)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01)

Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
by: Ghassan Jarred, et al.
Published: (2010-04-01)

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
by: Seyed Ali Sadjadi, et al.
Published: (2009-07-01)

Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan
by: Huang Shiou-Huei, et al.
Published: (2012-05-01)

Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners
by: Sophie L.M. Walker, et al.
Published: (2018-06-01)

Drug Utilization Evaluation of Angiotensin-Converting Enzyme Inhibitors and AngiotensinⅡ receptor blockers on Hypertensive Patients in Taiwan
by: Wen-Yi Chang, et al.
Published: (2010)

Comparisons of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with other Antihypertensive Agents on Chronic Dialysis Patients
by: Hui-Lin Hsiao, et al.
Published: (2011)

Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes
by: Özlem Bozkurt, et al.
Published: (2009-06-01)